10:06 AM EST - CanniMed Therapeutics Inc. : Released its financial results for the three months ended July 31, 2017. Sales of $4.8 million in the quarter were 80% higher than in the comparable period of the prior year and were 29% higher than the second quarter of 2017. Net loss for the loss was $1.4 million. CanniMed Therapeutics Inc.
shares T.CMED are trading unchanged at $8.85.
